Novel EGF pathway regulators modulate C. Elegans healthspan and lifespan via EGF receptor, PLC-γ, and IP3R activation

Hiroaki Iwasa, Simon Yu, Jian Xue, Monica Driscoll

Research output: Contribution to journalArticle

51 Citations (Scopus)

Abstract

Improving health of the rapidly growing aging population is a critical medical, social, and economic goal. Identification of genes that modulate healthspan, the period of mid-life vigor that precedes significant functional decline, will be an essential part of the effort to design anti-aging therapies. Because locomotory decline in humans is a major contributor to frailty and loss of independence and because slowing of movement is a conserved feature of aging across phyla, we screened for genetic interventions that extend locomotory healthspan of Caenorhabditis elegans. From a group of 54 genes previously noted to encode secreted proteins similar in sequence to extracellular domains of insulin receptor, we identified two genes for which RNAi knockdown delayed age-associated locomotory decline, conferring a high performance in advanced age phenotype (Hpa). Unexpectedly, we found that hpa-1 and hpa-2 act through the EGF pathway, rather than the insulin signaling pathway, to control systemic healthspan benefits without detectable developmental consequences. Further analysis revealed a potent role of EGF signaling, acting via downstream phospholipase C-c plc-3 and inositol-3-phosphate receptor itr-1, to promote healthy aging associated with low lipofuscin levels, enhanced physical performance, and extended lifespan. This study identifies HPA-1 and HPA-2 as novel negative regulators of EGF signaling and constitutes the first report of EGF signaling as a major pathway for healthy aging. Our data raise the possibility that EGF family members should be investigated for similar activities in higher organisms.

Original languageEnglish (US)
Pages (from-to)490-505
Number of pages16
JournalAging cell
Volume9
Issue number4
DOIs
StatePublished - Aug 1 2010

Fingerprint

Epidermal Growth Factor Receptor
Epidermal Growth Factor
Genes
Medical Economics
Lipofuscin
Genetic Engineering
Insulin Receptor
Caenorhabditis elegans
Type C Phospholipases
RNA Interference
Insulin
Phenotype
Health
Population
Proteins
Therapeutics

All Science Journal Classification (ASJC) codes

  • Aging
  • Cell Biology

Keywords

  • Aging
  • Behavioral decline
  • EGF signaling
  • IP3 signaling
  • Lipofuscin
  • Sarcopenia

Cite this

@article{0e7521e423604120b44011b66269c5e5,
title = "Novel EGF pathway regulators modulate C. Elegans healthspan and lifespan via EGF receptor, PLC-γ, and IP3R activation",
abstract = "Improving health of the rapidly growing aging population is a critical medical, social, and economic goal. Identification of genes that modulate healthspan, the period of mid-life vigor that precedes significant functional decline, will be an essential part of the effort to design anti-aging therapies. Because locomotory decline in humans is a major contributor to frailty and loss of independence and because slowing of movement is a conserved feature of aging across phyla, we screened for genetic interventions that extend locomotory healthspan of Caenorhabditis elegans. From a group of 54 genes previously noted to encode secreted proteins similar in sequence to extracellular domains of insulin receptor, we identified two genes for which RNAi knockdown delayed age-associated locomotory decline, conferring a high performance in advanced age phenotype (Hpa). Unexpectedly, we found that hpa-1 and hpa-2 act through the EGF pathway, rather than the insulin signaling pathway, to control systemic healthspan benefits without detectable developmental consequences. Further analysis revealed a potent role of EGF signaling, acting via downstream phospholipase C-c plc-3 and inositol-3-phosphate receptor itr-1, to promote healthy aging associated with low lipofuscin levels, enhanced physical performance, and extended lifespan. This study identifies HPA-1 and HPA-2 as novel negative regulators of EGF signaling and constitutes the first report of EGF signaling as a major pathway for healthy aging. Our data raise the possibility that EGF family members should be investigated for similar activities in higher organisms.",
keywords = "Aging, Behavioral decline, EGF signaling, IP3 signaling, Lipofuscin, Sarcopenia",
author = "Hiroaki Iwasa and Simon Yu and Jian Xue and Monica Driscoll",
year = "2010",
month = "8",
day = "1",
doi = "10.1111/j.1474-9726.2010.00575.x",
language = "English (US)",
volume = "9",
pages = "490--505",
journal = "Aging Cell",
issn = "1474-9718",
publisher = "Wiley-Blackwell",
number = "4",

}

Novel EGF pathway regulators modulate C. Elegans healthspan and lifespan via EGF receptor, PLC-γ, and IP3R activation. / Iwasa, Hiroaki; Yu, Simon; Xue, Jian; Driscoll, Monica.

In: Aging cell, Vol. 9, No. 4, 01.08.2010, p. 490-505.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Novel EGF pathway regulators modulate C. Elegans healthspan and lifespan via EGF receptor, PLC-γ, and IP3R activation

AU - Iwasa, Hiroaki

AU - Yu, Simon

AU - Xue, Jian

AU - Driscoll, Monica

PY - 2010/8/1

Y1 - 2010/8/1

N2 - Improving health of the rapidly growing aging population is a critical medical, social, and economic goal. Identification of genes that modulate healthspan, the period of mid-life vigor that precedes significant functional decline, will be an essential part of the effort to design anti-aging therapies. Because locomotory decline in humans is a major contributor to frailty and loss of independence and because slowing of movement is a conserved feature of aging across phyla, we screened for genetic interventions that extend locomotory healthspan of Caenorhabditis elegans. From a group of 54 genes previously noted to encode secreted proteins similar in sequence to extracellular domains of insulin receptor, we identified two genes for which RNAi knockdown delayed age-associated locomotory decline, conferring a high performance in advanced age phenotype (Hpa). Unexpectedly, we found that hpa-1 and hpa-2 act through the EGF pathway, rather than the insulin signaling pathway, to control systemic healthspan benefits without detectable developmental consequences. Further analysis revealed a potent role of EGF signaling, acting via downstream phospholipase C-c plc-3 and inositol-3-phosphate receptor itr-1, to promote healthy aging associated with low lipofuscin levels, enhanced physical performance, and extended lifespan. This study identifies HPA-1 and HPA-2 as novel negative regulators of EGF signaling and constitutes the first report of EGF signaling as a major pathway for healthy aging. Our data raise the possibility that EGF family members should be investigated for similar activities in higher organisms.

AB - Improving health of the rapidly growing aging population is a critical medical, social, and economic goal. Identification of genes that modulate healthspan, the period of mid-life vigor that precedes significant functional decline, will be an essential part of the effort to design anti-aging therapies. Because locomotory decline in humans is a major contributor to frailty and loss of independence and because slowing of movement is a conserved feature of aging across phyla, we screened for genetic interventions that extend locomotory healthspan of Caenorhabditis elegans. From a group of 54 genes previously noted to encode secreted proteins similar in sequence to extracellular domains of insulin receptor, we identified two genes for which RNAi knockdown delayed age-associated locomotory decline, conferring a high performance in advanced age phenotype (Hpa). Unexpectedly, we found that hpa-1 and hpa-2 act through the EGF pathway, rather than the insulin signaling pathway, to control systemic healthspan benefits without detectable developmental consequences. Further analysis revealed a potent role of EGF signaling, acting via downstream phospholipase C-c plc-3 and inositol-3-phosphate receptor itr-1, to promote healthy aging associated with low lipofuscin levels, enhanced physical performance, and extended lifespan. This study identifies HPA-1 and HPA-2 as novel negative regulators of EGF signaling and constitutes the first report of EGF signaling as a major pathway for healthy aging. Our data raise the possibility that EGF family members should be investigated for similar activities in higher organisms.

KW - Aging

KW - Behavioral decline

KW - EGF signaling

KW - IP3 signaling

KW - Lipofuscin

KW - Sarcopenia

UR - http://www.scopus.com/inward/record.url?scp=78049441103&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049441103&partnerID=8YFLogxK

U2 - 10.1111/j.1474-9726.2010.00575.x

DO - 10.1111/j.1474-9726.2010.00575.x

M3 - Article

C2 - 20497132

AN - SCOPUS:78049441103

VL - 9

SP - 490

EP - 505

JO - Aging Cell

JF - Aging Cell

SN - 1474-9718

IS - 4

ER -